Technology
Alterity Therapeutics to commercialise technology that breaks antibiotic resistance – Small Caps
The University of Queensland’s commercial vehicle UniQuest has granted a licence allowing Alterity Therapeutics (ASX: ATH) to use its zinc ionophore technology…
The University of Queenslands commercial vehicle UniQuest has granted a licence allowing Alterity Therapeutics (ASX: ATH) to use its zinc ionophore technology in combating superbugs.
UniQuest has given Alterity exclusive worldwide rights to use its zinc ionophore technology in developing and commercialising therapies that re-sensitise bacteria to antibiotics.
Once Alterity has begun receiving commercial revenue from commercialising the technology, it will make milestone and royalty payments to UniQuest…
-
Business14 hours ago10 ASX shares to buy after the market selloff
-
General17 hours ago‘We are here for you’: PM to bring help to flood zones
-
General16 hours agoWe’ve all talked about potential economic consequences for Australia of Trump’s policies. Now they’re happening
-
General13 hours agoStephanie Scott’s murder caused a ‘seismic’ shock in Leeton, and the hurt remains